000153690 001__ 153690
000153690 005__ 20240229123046.0
000153690 0247_ $$2doi$$a10.1016/j.lungcan.2020.01.021
000153690 0247_ $$2pmid$$apmid:32044589
000153690 0247_ $$2ISSN$$a0169-5002
000153690 0247_ $$2ISSN$$a1872-8332
000153690 037__ $$aDKFZ-2020-00394
000153690 041__ $$aeng
000153690 082__ $$a610
000153690 1001_ $$0P:(DE-He78)a79a61dd9934f6115f9383fd1dc21d76$$aFinke, Isabelle$$b0$$eFirst author
000153690 245__ $$aSocioeconomic differences and lung cancer survival in Germany: Investigation based on population-based clinical cancer registration.
000153690 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2020
000153690 3367_ $$2DRIVER$$aarticle
000153690 3367_ $$2DataCite$$aOutput Types/Journal article
000153690 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1603105395_12304
000153690 3367_ $$2BibTeX$$aARTICLE
000153690 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000153690 3367_ $$00$$2EndNote$$aJournal Article
000153690 500__ $$aVolume 142, April 2020, Pages 1-8#EA:C070#LA:C070#
000153690 520__ $$aStudies from several countries reported socioeconomic inequalities in lung cancer survival. Hypothesized reasons are differences in cancer care or tumor characteristics. We investigated associations of small-area deprivation and lung cancer survival in Germany and the possible impact of differences in patient, tumor or treatment factors.Patients registered with a primary tumor of the lung between 2000-2015 in three German population-based clinical cancer registries were included. Area-based socioeconomic deprivation on municipality level was measured with the categorized German Index of Multiple Deprivation. Association of deprivation with overall survival was investigated with Cox regression models.Overall, 22,905 patients were included. Five-year overall survival from the least to the most deprived quintile were 17.2%, 15.9%, 16.7%, 15.7%, and 14.4%. After adjustment for patient and tumor factors, the most deprived group had a lower survival compared to the least deprived group (Hazard Ratio (HR) 1.06, 95% confidence interval (CI) 1.01-1.11). Subgroup analyses revealed lower survival in the most deprived compared to the least deprived quintile in patients with stage I-III [HR: 1.14, 95% CI: 1.06-1.22]. The association persisted when restricting to patients receiving surgery but was attenuated for subgroups receiving either chemotherapy or radiotherapy.Our results indicate differences in lung cancer survival according to area deprivation in Germany, which were more pronounced in patients with I-III stage cancer. Future research should address in more detail the underlying reasons for the observed inequalities and possible approaches to overcome them.
000153690 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000153690 588__ $$aDataset connected to CrossRef, PubMed,
000153690 7001_ $$0P:(DE-He78)810dd5ca5d284a355124f982bfc3a8e6$$aBehrens, Gundula$$b1
000153690 7001_ $$aSchwettmann, Lars$$b2
000153690 7001_ $$aGerken, Michael$$b3
000153690 7001_ $$aPritzkuleit, Ron$$b4
000153690 7001_ $$aHolleczek, Bernd$$b5
000153690 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b6
000153690 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b7$$eLast author
000153690 7001_ $$aGroup, German Cancer Survival Working$$b8$$eCollaboration Author
000153690 773__ $$0PERI:(DE-600)2025812-4$$a10.1016/j.lungcan.2020.01.021$$gVol. 142, p. 1 - 8$$p1 - 8$$tLung cancer$$v142$$x0169-5002$$y2020
000153690 909CO $$ooai:inrepo02.dkfz.de:153690$$pVDB
000153690 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a79a61dd9934f6115f9383fd1dc21d76$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000153690 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)810dd5ca5d284a355124f982bfc3a8e6$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000153690 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000153690 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000153690 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000153690 9141_ $$y2020
000153690 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000153690 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000153690 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000153690 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLUNG CANCER : 2017
000153690 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000153690 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000153690 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000153690 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000153690 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000153690 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000153690 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000153690 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000153690 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000153690 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000153690 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000153690 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000153690 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000153690 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000153690 980__ $$ajournal
000153690 980__ $$aVDB
000153690 980__ $$aI:(DE-He78)C070-20160331
000153690 980__ $$aI:(DE-He78)C120-20160331
000153690 980__ $$aI:(DE-He78)HD01-20160331
000153690 980__ $$aUNRESTRICTED